These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 32690996)

  • 21. Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV-2 infection.
    Roussel M; Ferrant J; Reizine F; Le Gallou S; Dulong J; Carl S; Lesouhaitier M; Gregoire M; Bescher N; Verdy C; Latour M; Bézier I; Cornic M; Vinit A; Monvoisin C; Sawitzki B; Leonard S; Paul S; Feuillard J; Jeannet R; Daix T; Tiwari VK; Tadié JM; Cogné M; Tarte K
    Cell Rep Med; 2021 Jun; 2(6):100291. PubMed ID: 33977279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.
    Ting CT; Chen BS
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. α1-Antitrypsin: Key Player or Bystander in Acute Respiratory Distress Syndrome?
    Hogan G; Geoghegan P; Carroll TP; Clarke J; McElvaney OF; McElvaney OJ; McElvaney NG; Curley GF
    Anesthesiology; 2021 May; 134(5):792-808. PubMed ID: 33721888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful use of ECMO in the treatment of acute respiratory distress syndrome associated with SARS-CoV-2 in two pediatric cases.
    Stasiv M; Mishchuk V; Basa N; Lytvyn H
    Germs; 2022 Jun; 12(2):308-315. PubMed ID: 36504609
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Mardi A; Meidaninikjeh S; Nikfarjam S; Majidi Zolbanin N; Jafari R
    Viral Immunol; 2021 Dec; 34(10):679-688. PubMed ID: 34882013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pulmonary innate immune response in Sars-cov-2 infection].
    Bottino E; Ponce AA
    Rev Fac Cien Med Univ Nac Cordoba; 2022 Mar; 79(1):33-42. PubMed ID: 35312259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.
    Tamimi F; Abusamak M; Akkanti B; Chen Z; Yoo SH; Karmouty-Quintana H
    Br J Pharmacol; 2020 Nov; 177(21):4845-4850. PubMed ID: 32442317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Parsonage-Turner Syndrome following COVID-19 Infection: A Rare and Unique Case.
    Ansari B; Eishi Oskouei A; Moeinzadeh F
    Adv Biomed Res; 2022; 11():7. PubMed ID: 35284354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
    van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
    Elife; 2020 Apr; 9():. PubMed ID: 32338605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
    Agresti N; Lalezari JP; Amodeo PP; Mody K; Mosher SF; Seethamraju H; Kelly SA; Pourhassan NZ; Sudduth CD; Bovinet C; ElSharkawi AE; Patterson BK; Stephen R; Sacha JB; Wu HL; Gross SA; Dhody K
    J Transl Autoimmun; 2021; 4():100083. PubMed ID: 33521616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
    Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR
    Front Immunol; 2022; 13():888897. PubMed ID: 35663932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.
    Al-Kuraishy HM; Al-Gareeb AI; Al-Hussaniy HA; Al-Harcan NAH; Alexiou A; Batiha GE
    Int Immunopharmacol; 2022 Mar; 104():108516. PubMed ID: 35032828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 Infection Triggers Auto-Immune Response in ARDS.
    Juanes-Velasco P; Landeira-Viñuela A; García-Vaquero ML; Lecrevisse Q; Herrero R; Ferruelo A; Góngora R; Corrales F; Rivas JL; Lorente JA; Hernández ÁP; Fuentes M
    Front Immunol; 2022; 13():732197. PubMed ID: 35154090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of COVID-19-Related Severe Acute Respiratory Distress Syndrome in a Patient With Active Human Immunodeficiency Virus Infection.
    Panda R; Singh P; Saigal S; Karna ST
    Cureus; 2021 Sep; 13(9):e18045. PubMed ID: 34671530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection.
    Soto M; diZerega G; Rodgers KE
    J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972018. PubMed ID: 33169644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Immune Response and Effectiveness of COVID-19 Therapies.
    Tavasolian F; Hatam GR; Mosawi SH; Saadi MI; Abdollahi E; Jamialahmadi T; Sathyapalan T; Sahebkar A
    Adv Exp Med Biol; 2021; 1321():115-126. PubMed ID: 33656718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxemia and Cytokine Storm in COVID-19: Clinical Implications.
    Machado C; González-Quevedo A
    MEDICC Rev; 2021; 23(3-4):54-59. PubMed ID: 34516537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and in the post-COVID-19 recovery phase.
    Uzunova G; Pallanti S; Hollander E
    Int J Psychiatry Clin Pract; 2021 Jun; 25(2):115-131. PubMed ID: 33635172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of acute respiratory distress syndrome in patients with COVID-19 and influenza A (H7N9) virus infection.
    Ding L; Chen Y; Su N; Xu X; Yin J; Qiu J; Wang J; Zheng D
    Int J Infect Dis; 2022 Sep; 122():593-598. PubMed ID: 35793755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.